Compare · NTRB vs ZBH
NTRB vs ZBH
Side-by-side comparison of Nutriband Inc. (NTRB) and Zimmer Biomet Holdings Inc. (ZBH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NTRB and ZBH operate in Industrial Specialties (Health Care), so they compete in similar markets.
- ZBH is the larger of the two at $18.00B, about 236.2x NTRB ($76.2M).
- Over the past year, NTRB is down 14.5% and ZBH is down 7.6% - ZBH leads by 6.9 points.
- ZBH has been more active in the news (13 items in the past 4 weeks vs 4 for NTRB).
- ZBH has more recent analyst coverage (25 ratings vs 1 for NTRB).
- Company
- Nutriband Inc.
- Zimmer Biomet Holdings Inc.
- Price
- $6.21-1.58%
- $94.99+0.62%
- Market cap
- $76.2M
- $18.00B
- 1M return
- -17.26%
- +0.77%
- 1Y return
- -14.46%
- -7.55%
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 4
- 13
- Recent ratings
- 1
- 25
Nutriband Inc.
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain. The company has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. Nutriband Inc. was incorporated in 2016 and is headquartered in Orlando, Florida.
Zimmer Biomet Holdings Inc.
Zimmer Biomet Holdings, Inc., together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company provides orthopaedic reconstructive products, such as knee and hip replacement products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products, as well as surgical, bone cement, and office-based technology products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
Latest NTRB
- Nutriband Inc. announces exercise of warrants at $6.43 for Gross Proceeds of $1,753,274
- Nutriband Files New Patent Application to Strengthen Intellectual Property Protection of Its Transdermal Abuse Deterrent Technology
- Nutriband Marks Five Years on Nasdaq – CEO Letter to Shareholders
- SEC Form 25-NSE filed by Nutriband Inc.
- Nutriband Appoints Decorated Navy SEAL and Veterans Health Advocate Robert J. O'Neill to Advisory Board
- Nutriband Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Nutriband Confirms Warrants Will Expire September 30 Without Extension or Repricing
- Nutriband CEO, Gareth Sheridan to Attend the Nasdaq Life Sciences Advisory Board (LaB) Biotech Summit
- Nutriband Receives USPTO Notice of Publication of Commercial Brand Name Trademarks for Its Abuse Deterrent Fentanyl Patch
- Nutriband CEO, Gareth Sheridan to Present at the 2026 Georgia Life Sciences Summit as Part of the CEO Spotlight
Latest ZBH
- ZIMMER BIOMET AND THINK SURGICAL EXTEND EXCLUSIVE DISTRIBUTION AGREEMENT
- Barclays initiated coverage on Zimmer Biomet with a new price target
- Zimmer Biomet Announces Webcast and Conference Call of Third Quarter 2026 Financial Results
- SEC Form 4 filed by Zimmer Biomet Holdings Inc.
- SEC Form 3 filed by Zimmer Biomet Holdings Inc.
- SEC Form 3 filed by Zimmer Biomet Holdings Inc.
- SEC Form 4 filed by Director Farrell Michael J.
- SEC Form 4 filed by Director Hagemann Robert
- SEC Form 4 filed by Director Higgins Arthur J
- SEC Form 4 filed by Director Shapiro Louis